Humphrey Wong, MD
Critical Care Medicine · Davenport, IANPI 1013982610
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by AstraZeneca at 56.5% of the total. Among critical care medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $114.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Intuitive Surgical$8K
- Insmed, Inc.$772
- United Therapeutics Corporation$708
- Regeneron Healthcare Solutions, Inc.$401
- Boehringer Ingelheim$253
- plus $3K from 39 others
What the payments were for
- Speaking & faculty fees$15,95051%
- Travel & lodging$3,44711%
- Food & beverage$7,80625%
- Education$4,16313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$16,720
- Da Vinci Surgical System$7,553
- Arikayce$476
- BREZTRI$309
- TEZSPIRE$309
- FASENRA$309
- PURIFIED CORTROPHIN GEL$125
- CARDIOMEMS$124
- REBYOTA$116
- HealthMyne$110
- GIAPREZA$103
How this compares
$31,367 in reported general payments places this provider in the 95th percentile of 33 critical care medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 45 | $575,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 598 | $447,890 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $190,160 |
| AdempasRiociguat | 12 | $163,351 |
| Pirfenidone | 20 | $132,950 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 166 | $126,811 |
| Dupixent PenDupilumab | 32 | $117,929 |
| Breo ElliptaFluticasone/Vilanterol | 221 | $108,721 |
| Spiriva RespimatTiotropium Bromide | 157 | $107,395 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 137 | $83,383 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 74 | $51,201 |
| Advair HfaFluticasone Propion/Salmeterol | 91 | $45,590 |
| SymbicortBudesonide/Formoterol Fumarate | 154 | $45,093 |
| EliquisApixaban | 50 | $42,601 |
| Atrovent HfaIpratropium Bromide | 65 | $36,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $253 | $753,045309 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $158 | $661,8731,042 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $17,714 | $201,364373 claims |
| Grifols USA, LLCProlastin C | $30 | $190,16013 claims |
| BayerAdempas | $37 | $163,35112 claims |
| PfizerEliquis | $226 | $42,60150 claims |
| MerckDulera | $117 | $17,30647 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 critical care medicine providers in Iowa.
Other critical care medicine in Davenport
- Brian GrossDavenport$1K
- Andrea OdvarkoDavenport$154
- Amal El-BakushCedar Rapids$19K
- Lovkesh AroraIowa City$5K
- Charles RappaportIowa City$4K
- David KaczkaIowa City$4K
- Amith George JacobIowa City$3K
- Katherine KavanaughCedar Rapids$2K
- Gregory SchmidtIowa City$2K
- Swaroopa Rani NalamalapuWaterloo$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.